David A. Siegel Arcellx, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Arcellx, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 4,500 shares of ACLX stock, worth $342,720. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,500
Previous 5,300
15.09%
Holding current value
$342,720
Previous $292,000
28.42%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ACLX
# of Institutions
204Shares Held
44.2MCall Options Held
2.23MPut Options Held
907K-
Paradigm Biocapital Advisors LP New York, NY4MShares$305 Million12.04% of portfolio
-
Perceptive Advisors LLC New York, NY3.89MShares$296 Million8.48% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$285 Million23.89% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$268 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.46MShares$188 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.34B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...